Evidence map›Paper›PMID 36083875›Full record

ArticlePloS one2022

Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level.

Alina Szewczyk-Dąbrowska, Wiktoria Budziar, Krzysztof Baniecki, Aleksandra Pikies, Marek Harhala, Natalia Jędruchniewicz, Zuzanna Kaźmierczak, Katarzyna Gembara, Tomasz Klimek, Wojciech Witkiewicz and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Alina Szewczyk-DąbrowskaRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.ORCID 0000-0001-7629-4912
Wiktoria BudziarRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Krzysztof BanieckiHealthcare Centre in Bolesławiec, Bolesławiec, Poland.
Aleksandra PikiesHealthcare Centre in Bolesławiec, Bolesławiec, Poland.
Marek HarhalaRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Natalia JędruchniewiczRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.ORCID 0000-0002-6515-5762
Zuzanna KaźmierczakRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Katarzyna GembaraRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Tomasz KlimekRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Wojciech WitkiewiczRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.
Artur NahoreckiHealthcare Centre in Bolesławiec, Bolesławiec, Poland.
Kamil BarczykHealthcare Centre in Bolesławiec, Bolesławiec, Poland.
Urszula Grata-BorkowskaDepartment of Family Medicine, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0003-3783-0481
Krystyna DąbrowskaRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, Poland.ORCID 0000-0002-1518-3183
Łukasiewicz Research Network – PORT Polish Center for Technology Development · PLWroclaw Research Centre EIT+ (Poland) · PLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune response and specific antibody production in COVID-19 are among the key factors that determine both prognostics for individual patients and the global perspective for controlling the pandemics. So called "dark figure", that is, a part of population that has been infected but not registered by the health care system, make it difficult to estimate herd immunity and to predict pandemic trajectories. Here we present a follow up study of population screening for hidden herd immunity to SARS-CoV-2 in individuals who had never been positively diagnosed against SARS-CoV-2; the first screening was in May 2021, and the follow up in December 2021. We found that specific antibodies targeting SARS-CoV-2 detected in May as the "dark figure" cannot be considered important 7 months later due to their significant drop. On the other hand, among participants who at the first screening were negative for anti-SARS-CoV-2 IgG, and who have never been diagnosed for SARS-CoV-2 infection nor vaccinated, 26% were found positive for anti-SARS-CoV-2 IgG. This can be attributed to of the "dark figure" of the recent, fourth wave of the pandemic that occurred in Poland shortly before the study in December. Participants who were vaccinated between May and December demonstrated however higher levels of antibodies, than those who undergone mild or asymptomatic (thus unregistered) infection. Only 7% of these vaccinated participants demonstrated antibodies that resulted from infection (anti-NCP). The highest levels of protection were observed in the group that had been infected with SARS-CoV-2 before May 2021 and also fully vaccinated between May and December. These observations demonstrate that the hidden fraction of herd immunity is considerable, however its potential to suppress the pandemics is limited, highlighting the key role of vaccinations.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralFollow-Up StudiesHumansImmunoglobulin GSeroconversionAntibodies, ViralImmunoglobulin G

Identifiers

PMID36083875
PMCPMC9462561
OpenAlexW4295066764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.